Evidence map›Paper›PMID 38965553›Full record

ReviewJournal of nanobiotechnology2024

Exosome for mRNA delivery: strategies and therapeutic applications.

Zoya Iqbal, Khurrum Rehman, Ayesha Mahmood, Maryam Shabbir, Yujie Liang, Li Duan, Hui Zeng

Abstract readReview
In one paragraph

Review in Journal of nanobiotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zoya IqbalDepartment of Orthopedics, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, 518035, China.
Khurrum RehmanDepartment of Allied Health Sciences, The University of Agriculture, D.I.Khan, Pakistan.
Ayesha MahmoodDepartment of Pharmacy, The University of Lahore, Lahore Campus, Lahore, Pakistan.
Maryam ShabbirDepartment of Pharmacy, The University of Lahore, Lahore Campus, Lahore, Pakistan.
Yujie LiangDepartment of Child and Adolescent Psychiatry, Shenzhen Clinical Research Center for Mental Disorders, Shenzhen Kangning Hospital, Shenzhen Mental Health Center, Shenzhen, 518020, China. liangyjie@126.com.
Li DuanDepartment of Orthopedics, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, 518035, China. duanl@szu.edu.cn.
Hui ZengDepartment of Orthopedics, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, 518035, China. zenghui_36@163.com.

Funding

Guangdong Basic and Applied Basic Research Foundation 2023A1515011936Guangdong International Cooperation Project No. 2021A0505030011Ministry of Science and Technology of the People's Republic of China, Project QN2022032011LNational Natural Science Foundation of China No. 81972116the Fund of Development and Reform Commission of Shenzhen Municipality(Shenzhen Engineering Research Center for Precision Psychiatric Technology ). XMHT20220104028the Shenzhen Fund for Guangdong Provincial High Level Clinical Key Specialties No. SZGSP013the Shenzhen Key Medical Discipline Construction Fund No. SZXK042
6 · The paper itself

Abstract

Messenger RNA (mRNA) has emerged as a promising therapeutic molecule with numerous clinical applications in treating central nervous system disorders, tumors, COVID-19, and other diseases. mRNA therapies must be encapsulated into safe, stable, and effective delivery vehicles to preserve the cargo from degradation and prevent immunogenicity. Exosomes have gained growing attention in mRNA delivery because of their good biocompatibility, low immunogenicity, small size, unique capacity to traverse physiological barriers, and cell-specific tropism. Moreover, these exosomes can be engineered to utilize the natural carriers to target specific cells or tissues. This targeted approach will enhance the efficacy and reduce the side effects of mRNAs. However, difficulties such as a lack of consistent and reliable methods for exosome purification and the efficient encapsulation of large mRNAs into exosomes must be addressed. This article outlines current breakthroughs in cell-derived vesicle-mediated mRNA delivery and its biomedical applications.

Indexed as

ExosomesRNA, MessengerSARS-CoV-2AnimalsCOVID-19Drug Delivery SystemsGene Transfer TechniquesHumansNeoplasmsRNA, MessengerExosomesmRNATargeted delivery

Identifiers

PMID38965553
PMCPMC11225225

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.